Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications

Table 1 Concomitant use of proton-pump inhibitors, H2-receptor antagonists or mucoprotective drugs in patients taking low-dose aspirin

Drug name	Number of prescriptions	Percentage of prescriptions with combination therapy to total aspirin prescriptions (%)
H2RA	36	0.12a
Oral PPIs	708	2.36
Pantoprazole	342	1.14
Esomeprazole	157	0.52
Omeprazole	121	0.40
Rabeprazole	85	0.28
Lansoprazole	3	0.01
i.v. PPIs	139	0.46
Pantoprazole sodium	132	0.44
Omeprazole sodium	7	0.02
MPs	120	0.40c
Hydrotalcite	43	0.14
Teprenone	33	0.11
Marzulene-S	25	0.083
Sucralfate	11	0.037
Gefarnate	5	0.017
Rebamipide	3	0.010
Misoprostol	0	0
PPI/MPs	36	0.12
Teprenone	11	0.037
Hydrotalcite	9	0.030
Rebamipide	5	0.017
Marzulene-S	4	0.013
Gefarnate	4	0.013
Sucralfate	3	0.010
Misoprostol	0	0

^aP < 0.05 vs oral proton-pump inhibitors (PPIs) plus i.v. PPIs;

^cP < 0.05 vs oral PPIs plus i.v. PPIs. MPs: Mucoprotective drugs; H2RA: H2-receptor antagonists.